H&R WASAG saw its pre-tax profits halve in the first six months
of this year, hit by high and volatile raw material costs that
impacted its flagship pharmachem division.
Recordati is expecting to sell off its pharmaceutical chemical
operations by the end of next year or early in 2004, according to
the company's chief executive, who expects €80-€90m in proceeds for
the sale.
Millions of dollars are being spent unnecessarily each year on
treatments for high blood pressure says research published this
week in BMC Health Services Research.
The creditors of Australian over-the-counter medicines and vitamins
manufacturer Pan Pharmaceuticals have rejected a rescue bid for the
company at a meeting held last week. Another meeting is due to be
held later today.
Chiron's headquarters is hit by two homemade bombs, with an animal
rights group claiming responsibility. The blasts caused no
casualties and only minor damage to property, but represent an
alarming escalation in the tactics used...
French company Flamel Technologies has added another high-profile
client for its drug delivery technology spurring another leap in
its shares that have already climbed almost 800 per cent over the
last 12 months.
Schering-Plough has lowered its financial forecasts for the second
time and unveiled a fresh round of cost cutting in an attempt to
stabilise its finances.
Top pharmaceutical manufacturing plants strive to achieve efficient
operations that result in increased profitability as well as
superior product quality and satisfied customers. These are the
findings of a new study from market research...
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and
biosciences activities.
Italy's Recordati has said that it plans to sell off its
pharmaceutical chemical activities over the next few months in
order to concentrate on pharmaceuticals.
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
The difficulties facing Lonza came into clear focus today as the
company published its half-year results, with sales down across its
custom manufacturing, organic chemicals and polymers businesses.
Chemical major BASF has expanded the range of products it offers to
pharmaceutical clients with the $65 million (€58m) purchase of
Callery Chemical from Mine Safety Appliances.
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
production.
Danish pharmaceutical companies increased their sales to overseas
countries by 20 per cent in the first four months of this year
compared with the same period of 2002, according to Invest In
Denmark.
Germany's third largest chemical company has raised € 2 bn of
credit lines by means of a syndicated facility with a group of
leading international banks.
Chiron's has completed its acquisition of UK vaccine and drug
delivery specialist PowderJect, making it the second-largest
manufacturer of flu vaccines worldwide.
Caliper Technologies has been given the go-ahead by the US federal
Trade Commission for its $71 million cash and stock acquisition of
Zymark, a specialist in laboratory automation and robotics
equipment.
DSM has taken a 25 per cent interest in Nijmegen, Netherlands-based
Chiralix in move which both expands DSM's capabilities in
early-stage drug development and Chiralix' position in
stereochemistry
There is a growing trend towards patients self-medicating with
over-the-counter products rather than asking their doctors for a
prescription medication, and this promises to benefit companies
involved in pharmaceutical packaging,...
Applied chemistry company Solutia has completed the latest phase of
a new containment facility to support the supply of highly potent
active pharmaceutical ingredients
GeneMedix and Penang Development of Malaysia have signed a letter
of intent that will see the two establish a new company in the
latter country's second city, at a cost of $34 million (€29m), for
the development, manufacture...
US biotechnology company Biogen has decided to postpone
construction of a large production plant at Hillerød in Denmark,
just three months after breaking ground on the facility
Transgenic drug production company PPL Therapeutics has been rocked
by a decision by Germany's Bayer to walk away from their protein
development partnership, placing the future of the Scottish firm at
risk
The demands of the pharmaceutical industry are driving strong
growth in the market for outsourced chiral technologies, according
to a report from Frost & Sullivan
DSM Biologics has dissolved its relationship with Qiagen and
Valentis regarding the pAlliance, a consortium supplying
ultra-pure, stable DNA plasmids and formulated DNA
Great Lakes Fine Chemicals has invested $8 million ($6.7m) in a
program aimed at upgrading its pharmaceutical ingredient
manufacturing facilities in Holywel, Wales
Unigen Pharmaceuticals has expanded its sales presence in Europe
and Latin America by signing agency and distribution agreements
with six international corporate partners
ConjuChem, a company specialised in improving the formulation of
peptide drugs, has said that it is aiming to raise around C$12
million (€7.6m) in a new private placement round
Switzerland's Bachem SA, which specialises in the manufacture and
sale of bulk peptides and related organic chemicals as active
ingredients for the pharmaceutical industry, has announced that it
expects full-year sales growth...
Belgian pharmaceuticals and chemicals group UCB has said it expects
its profit in 2003 to be at a level comparable to those of the
previous year, influenced by the unfavourable economic climate, but
especially affected by the fall...
Protherics has said that it plans to expand its plant in Llandysul,
south Wales, to reduce the manufacturing cost of its products and
boost its profits
With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...
